Close Menu

NEW YORK — Specialty pharmaceutical firm Aytu BioScience said on Tuesday that it has exclusively licensed the US distribution rights for a point-of-care SARS-Cov-2 immunoassay developed by China's Zhejiang Orient Gene Biotech.

Englewood, California-based Aytu licensed the US rights to the test from Hong Kong's LB Resources, which holds the test's North American rights. Aytu has right to distribute the test in the US for three years with three-year autorenewals thereafter.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Sponsored by
Beckman Coulter

In this webinar session, Dr. David Harris and Dr. Ryan Sprissler, who led the student and employee testing program at University of Arizona, will discuss how the university has remained physically open with nearly 25 percent of its population on campus, while keeping infection rates below 2 percent.